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Abstract
Individuals having a genetic predisposition to cancer and their partners face challenging decisions regarding their wish to have
children. This study aimed to determine the effects of an online decision aid to support couples in making an informed decision
regarding their reproductive options. A nationwide pretest-posttest study was conducted in the Netherlands among 131 partic-
ipants between November 2016 and May 2018. Couples were eligible for participation if one partner had a pathogenic variant
predisposing for an autosomal dominant hereditary cancer syndrome. Participants completed a questionnaire before use (T0), and
at 3 months (T3) after use of the decision aid to assess the primary outcome measure informed decision-making, and the
secondary outcome measures decisional conflict, knowledge, realistic expectations, level of deliberation, and decision self-
efficacy. T0–T3 comparisons show an overall positive effect for all outcome measures (all ps < 0.05; knowledge (ES = −
1.05), decisional conflict (ES = 0.99), participants’ decision self-efficacy (ES = −0.55), level of deliberation (ES = − 0.50),
and realistic expectations (ES = − 0.44). Informed decision-making increased over time and 58.0% of the participants made an
informed reproductive decision at T3. The online decision aid seems to be an appropriate tool to complement standard repro-
ductive counseling to support our target group in making an informed reproductive decision. Use of the decision aid may lessen
the negative psychological impact of decision-making on couples’ daily life and wellbeing.
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Background
Decisional support strategies (e.g., use of decision aids) are
designed to help patients in making specific and deliberative
choices regarding their health(care) and can be effective in
promoting informed and shared decision-making (ISDM)
(O’Connor and Jacobsen 2003; Juraskova et al. 2014;
Stacey et al. 2017). Patient decision aids are particularly useful
to support patients in decision-making regarding choices that
are preference-sensitive and value-laden. These characteristics
are exemplary for reproductive decision-making among per-
sons with an autosomal dominant predisposition for hereditary
cancer and their partners, as they are faced with a 50% risk of
transmitting the pathogenic variant in one of the cancer genes
to their offspring.
Three reproductive options are available for couples who
strive for a child that is genetically related to both partners: (1)
natural conception without genetic testing, implying accep-
tance of the risk of passing on the pathogenic variant to off-
spring; (2) prenatal diagnosis (PND), with the possibility to
terminate the pregnancy if the fetus is affected by the patho-
genic variant; and (3) preimplantation genetic testing (PGT),
offering couples the option to obtain embryos by in vitro fer-
tilization (IVF) and test them for the familial pathogenic var-
iant. Only embryos without the pathogenic variant are trans-
ferred into the uterus. PGT is a physically intensive and rela-
tively lengthy trajectory with a chance of an ongoing pregnan-
cy of approximately 25% per treatment (De Rycke et al.
2015). However, PGT circumvents the emotional and physi-
cal burden of a pregnancy termination after prenatal testing
(de Die-Smulders et al. 2013). PGT and PND are common for
hereditary cancer; PGT for hereditary cancer predispositions
is possible in the Netherlands since 2008. Since this legaliza-
tion in the Netherlands, PGT for hereditary breast and ovarian
cancer evolved into one of the most often applied PGT indi-
cations. PND is also possible for some types of hereditary
cancer but is used far less than PGT. During counseling, most
couples of reproductive age receive information on the PGT
and PND procedures (PGD Nederland 2018).
Previous studies among couples who are aware that one of
both partners has a genetic predisposition to cancer and who
have a high genetic risk of transmitting this predisposition to
their offspring, indicated that couples experience difficulties
with reproductive decision-making (Derks-Smeets et al. 2014;
Gietel-Habets et al. 2018; Dekeuwer and Bateman 2013;
Ormondroyd et al. 2012; Dommering et al. 2010; Donnelly
et al. 2013; Van Asperen et al. 2002). Couples have to cope
with the increased risk of developing cancer of one of the
partners and additionally are worried about the risk of passing
on the predisposition to cancer to their offspring (Smith et al.
2004). Different physical, psychological, social, moral/ethical,
and practical motives and considerations are taken into ac-
count when deciding on a reproductive option, which makes
this a challenging process. The decision can have a major
emotional impact as couples may experience feelings of guilt
or doubt up to years after making their decision (Derks-
Smeets et al. 2014). Incorporating an online decision aid in
the reproductive decision-making process may optimize the
quality of the reproductive decision itself, as well as improve
the overall reproductive decision-making process (Derks-
Smeets et al. 2014; Quinn et al. 2010).
The present study is part of a larger project on the devel-
opment and implementation of an online decision aid with the
aim of supporting couples who are aware that one of them has
a genetic predisposition to cancer, to decide on the personally
most suitable reproductive option (Reumkens et al. 2018;
Reumkens et al. 2019a). In a previous study, short-term effects
of the online decision aid in supporting informed reproductive
decision-making among our target group were investigated
(Reumkens et al. 2019b). In this study, we report on the effects
on informed decision-making by both partners.
Methods
A nationwide pretest-posttest study was conducted in the
Netherlands between November 2016 and May 2018 among
persons who have a genetic predisposition to cancer and their
partners with a wish to have children.
Participants and procedures
Eligible couples were recruited during or after oncogenetic
consultation in one of the Clinical Genetics Departments in
the Netherlands (i.e., all nine departments participated in the
study). Healthcare providers involved in the oncogenetic
counseling (i.e., clinical geneticists, genetic counselors, and
social workers) recruited couples. Couples were eligible for
participation if one partner had a pathogenic variant predis-
posing for an autosomal dominant hereditary cancer syn-
drome for which the reproductive options (PND/PGT) are
available in the Netherlands. Furthermore, couples had to have
the intention to try to conceive within 5 years, had to be 18
years or older, had not yet made a decision regarding their
preferred reproductive option, and needed to have sufficient
knowledge of the Dutch language.
Couples were provided with an information brochure by
their healthcare provider, including a link to an online regis-
tration page, with an explanation of the study procedure.
Although participation of both partners was encouraged, par-
ticipation of one partner (regardless of being carrier) was
allowed. After registration, both partners received an informed
consent form by e-mail. After providing online informed con-
sent, both partners were individually directed to an online
baseline questionnaire (T0). They received a personal login
code to access the decision aid after completing the baseline
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questionnaire. Questionnaires were completed separately by
both partners but it was allowed to use the decision aid togeth-
er. Immediately after use (T1), 2 weeks (T2), and 3 months
after use of the decision aid (T3), participants were again
directed to an online questionnaire. In this paper we will com-
pare outcome measures at T0 and T3, comparisons of T0–T1
and T0–T2 are described elsewhere (Reumkens et al. 2019b).
Findings regarding the outcome informed decision-making
could not be compared to T1 and T2 since not all concepts
of informed decision-making (knowledge, deliberation, and
value consistency) were assessed at T1 and T2. A reminder
was sent to participants who did not complete T3 within 3
weeks after invitation. After completion of the study, partici-
pants received an incentive of 15 euros in vouchers.
Content of the decision aid
For an explanation of the developmental process and the con-
tent of the online decision aid, see Reumkens et al. 2018
(Reumkens et al. 2019a). In short, the decision aid contained:
1. Information about the risk of transmitting the pathogenic
variant to their offspring and couples’ reproductive op-
tions to have genetically related children.
2. Treatment burden of reproductive options and the chances
of different outcomes (e.g., risk of miscarriage after PND)
presented in different formats using text and videos (e.g.,
verbal, and population diagrams) (Reumkens et al. 2018;
Trevena et al. 2013).
3. An option grid of important features of each option.
4. Value clarification exercises (VCE) (Fagerlin et al. 2013).
The VCE includes 18 statements representing values and
motives considered important for reproductive decision-
making (Derks-Smeets et al. 2014).
5. The possibility to generate a combined overview of both
partners’ responses on the VCE.
6. A question prompt sheet, providing examples of ques-
tions and requests for additional information and space
for own questions.
7. Information regarding the scientific resources used to un-
derpin the content of the DA, information on the develop-
ment team, funding, and contact information.
Questionnaires
Baseline characteristics assessed at T0 were gender, age, ed-
ucational level, carrier status, disease type, history of cancer in
the at risk person, reproductive history, number of children,
and future planning to have children. Couples were further-
more asked if they already had had a consultation with a
healthcare provider in which the reproductive options were
discussed.
The primary outcome measure was informed decision-
making, and secondary outcome measures were decisional
conflict, knowledge of the reproductive options, realistic ex-
pectations, level of deliberation, and decision self-efficacy. An
overview of the content of the questionnaires is provided in
Table 1.
Informed decision-making was measured at T0 and T3
by analyzing the outcomes knowledge, deliberation, and
attitude towards the reproductive options (Van den Berg
et al. 2006; Marteau et al. 2001). A reproductive decision
was considered to be informed if a participant had a suf-
ficient knowledge level, a high level of deliberation, and
if the reproductive option was value-consistent (Van den
Berg et al. 2006). To measure informed decision-making,
knowledge and deliberation were recoded into dichoto-
mous variables. Based on Abbott’s formula, knowledge
levels of ≥ 12 (total 15) were considered to be sufficient
(Frary 1988). Furthermore, based on median scores, de-
liberation scores of ≥ 19 (total 30) were considered to be
high levels of deliberation. Participants’ (preferred) repro-
ductive option was classified as value-consistent if partic-
ipants had a positive attitude (score ≥ 15: total 28) to-
wards this option. It should be noted that behavioral im-
plementation or adherence to the reproductive decision
(i.e., uptake of the test (PND) or treatment (PGT)) is un-
likely to have occurred for all couples during the study
period. Therefore, it is only possible to measure informed
choice as defined by Marteau et al. 2001 (i.e., an informed
choice is one that is based on relevant knowledge, con-
sistent with the decision maker’s values and behaviorally
implemented) for couples who reported at T3 that they try
to conceive or started the PGT trajectory (Marteau et al.
2001).
Statistical analyses
Data from the baseline characteristics were analyzed bymeans
of descriptive statistics and quantified as mean and standard
deviation or absolute number and percentage. To decide what
statistical model could best be used to analyze data that are
clustered both within participants (i.e., before–after) and with-
in couples, we compared twomodels: one linear mixed-effects
model in which clustering within participants over time and
within couples was corrected for, and one model without cor-
rection for clustering within couples. Both models yielded
similar results. A likelihood-ratio test showed that correction
for the clustering of observations within couples did not lead
to a better model fit (likelihood ratio = 0.00, p = 1.000). Since
it was sufficient to take the within-participant clustering into
account, paired sample t tests were conducted to compute
differences between the first and subsequent measurement
for the continuous variables. To assess the effects of the deci-
sion aid for several subgroups, we first split our sample into
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two groups (e.g., males and females) before conducting a
paired sample t test for each group. An exact McNemar’s test
was performed to assess the effects of the decision aid on
informed decision-making. Cohen’s d was used to report ef-
fect sizes; an effect size quantifies the strength of an effect
between group means. Analyses were performed using IBM
SPSS version 23 and R version 3.3.3. p values less than 0.05
were considered significant.
Results
Baseline characteristics
T0 was completed by 131 participants and 93 partici-
pants completed T3 (29.0% dropout). At T0, 122 par-
ticipants were part of a couple; nine participants took
part without their partner. Over half of the participants
were female (55.0%). Males were slightly older com-
pared with females (32.3 vs. 29.6 years). More than half
of the participants had a high education level (57.3%).
The most frequently reported hereditary cancer syn-
drome was hereditary breast and ovarian cancer
(HBOC) (84.7%). The majority (73.3%) indicated that
they wanted to have children within 2 years and
16.8% already had offspring. The majority of the par-
ticipants (77%) already had a consultation in which the
reproductive options were discussed. An overview of
participants’ baseline characteristics is provided in
Table 2.
Effects of the decision aid
Primary outcome measure: informed decision-making
For 14.4% of the participants, the reproductive decision (i.e.,
the preferred reproductive option, e.g., PGT) at baseline met
the conditions for informed decision-making (Fig. 1). Only
17.8% of the participants made a knowledge-based decision,
17.8% made a decision that was knowledge-based and delib-
erated, and 14.4% made a decision that was knowledge-based
and deliberated and value-consistent, thereby meeting all
three prerequisites for informed decision-making at baseline.
As the items of the Deliberation Scale, essential to measure
informed decision-making, were not fully completed by all
couples, we were able to include a total of 90 participants at
baseline and 69 participants at T3.
Informed decision-making significantly increased over
time (p < 0.001). At T3, 63.8% of the participants made a
knowledge-based decision, 62.3% made a decision that was
knowledge-based and deliberated, and 58.0%made a decision
that was knowledge-based and deliberated and value-consis-
tent, and therefore meeting all three prerequisites for informed
decision-making (Fig. 2).
Informed decision-making regarding the reproductive op-
tions was furthermore assessed at the couple level (i.e., both
partners of a couple made an informed reproductive decision)
and significantly increased over time (p < 0.001). A total of 76
participants participated as a couple at T0 (38 couples). In 26
of these 38 couples (68.4%), both partners had the same pre-
ferred reproductive option. Only two out of these 26 couples
Table 1 Questionnaires
Questionnaire Number of items Answering scale Scoring Cronbach’s α
Decisional conflict Decisional Conflict Scale
(O’Connor 1995).
16 0 (strongly agree)–4 (strongly disagree) 0–100 0.85
Decisional conflict excl. the
effective decision
subscale*
Decisional Conflict Scale
(O’Connor 1995).
12 0 (strongly agree)–4 (strongly disagree) 0–100 0.91
Knowledge of the three
reproductive options
Gietel-Habets et al. 2017
(Gietel-Habets et al. 2017).
15 1 = correct, 2 = incorrect, 3 = not sure
(recoded into 0 = incorrect, 1 =
correct)
0–15 -
Realistic expectations Realistic Expectations Scale
(O’Connor 2002).
3 Variable (recoded into 0 = incorrect, 1 =
correct)
0–3 -
Level of deliberation Deliberation Scale (Van den
berg et al. 2006).
6 1 (totally disagree)–5 (totally agree) 6–30 0.91
Decision self-efficacy Decision Self-Efficacy Scale
(Bunn and O’Connor
1996).
11 0 (not at all confident)–4 (very confident) 0–100 0.90
Attitude regarding the
reproductive options
Attitude Scale (Marteau et al.
2001).
4 per reproductive
option (total
12)
1 (e.g., beneficial and pleasant)–7 (e.g.,
harmful and unpleasant)
4–28 -
*As the items in the effective decision subscale from the Decisional Conflict Scale could not be completed by couples who did not have a preferred
reproductive option in mind, a combined score was also calculated for the 4 other subscales. These 12 items were summed, divided by 12, and multiplied
by 25. Total scores ranged from 0 (no decisional conflict) to 100 (extremely high decisional conflict).
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met the conditions for informed decision-making for both
partners at baseline (5.3% of total; 7.7% of couples agreeing
on the same reproductive option). A total of 58 participants
participated as a couple at T3 (29 couples). In 25 of 29 couples
(86.2%), both partners preferred the same reproductive option.
Ten out of these 25 couples met the conditions for informed
decision-making for both partners (34.5% of total; 40.0% of
couples agreeing on the same reproductive option). Nineteen
out of these 25 couples (76.0%) behaviorally implemented
their reproductive decision at T3 (i.e., trying to conceive or
started the PGT trajectory). Seven of these 19 couples met the
conditions for informed decision-making for both partners at
T3 (24.1% of total couples; 36.8% of couples who implement-
ed their decision (e.g., starting with PGT trajectory).
Secondary outcome measures
The decision aid showed significant effects for all secondary
outcome measures. The largest effect size was found for
knowledge (ES = − 1.05), followed by decisional conflict
(ES = 0.99), participants’ decision self-efficacy (ES = −
0.55), level of deliberation (ES = − 0.50), and realistic expec-
tations (ES = − 0.44) (Table 3).
Subgroup analysis
When analyzing the effects of the decision aid for various
subgroups on the outcome measures decisional conflict,
knowledge, realistic expectations, level of deliberation, and
decision self-efficacy, significant effects were found for all
outcomes (all ps < 0.05). These significant effects were found
for males and females, low/middle educated and high educat-
ed participants, carriers and partners of carriers, participants
with and without a history of cancer, and participants who had
had a consultation with a health care provider regarding the
reproductive options at baseline or in-between T0 and T3.
Participants who had not had a consultation with a healthcare
provider at baseline or in-between T0 and T3 showed signif-
icant effects reducing decisional conflict and increasing
knowledge, realistic expectations, and level of deliberation.
No significant effects were found for decision self-efficacy
(p = 0.478 respectively p = 0.190).
A significant effect was found for all outcome mea-
sures (all ps < 0.05) for participants who plan to have
children in the near future (≤ 2 years) whereas no effect
was found for realistic expectations (p = 0.261), level of
deliberation (p = 0.095), and decisional self-efficacy (p
= 0.478) for participants who plan to have children in
the more distant future (> 2 years).
For both groups, the confidence in their ability to make a
decision was already high at baseline (M = 83.8 and M =
78.1), although their baseline knowledge was relatively low
(M = 6.3 and M = 5.2) and increased at T3 (M = 9.0 and M =
9.2). The confidence in their ability to make a reproductive
decision among participants with a more distant wish to have
Table 2 Participants’ characteristics at baseline
Sample (%) (n =
131)
Gender
Male 59 (45.0)
Female 72 (55.0)
Age (years)
Male 32.3 (SD = 3.7)
Female 29.6 (SD = 3.3)
Education1
Low/middle 56 (42.7)
High 75 (57.3)
Carrier status
Male carrier 40 (30.5)
Female carrier 91 (69.5)
Hereditary cancer types
Hereditary breast and ovarian cancer 112 (85.5)
Hereditary nonpolyposis colorectal cancer/lynch
syndrome
10 (7.6)
Familial adenomatous polyposis 2 (1.5)
Familial atypical multiple mole/melanoma syn-
drome
1 (0.8)
Li-Fraumeni syndrome 2 (1.5)
Hereditary diffuse gastric cancer 2 (1.5)
Hereditary leiomyomatosis and renal cell
carcinoma
2 (1.5)
Have (had) cancer
Yes 18 (13.7)
No 113 (86.3)
Received counseling
Yes 101 (77.1)
No 30 (22.9)
Reproductive history
Children
Yes 22 (16.8)
No 109 (83.2)
Planning to have children
Trying to conceive 13 (9.9)
Plan to have children within two years 83 (63.4)
Plan to have children within five years 29 (22.1)
Maybe, not sure yet 4 (3.1)
Otherwise 2 (1.5)
Preferred reproductive option
Natural conception without genetic testing 31
PND 2
PGT 82
I don’t know 15
Missing 1
1 In 15 couples, both partners were low educated
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children slightly lowered (M= 81.06) and did not significantly
increase for participants who had not had a consultation with a
healthcare provider at baseline or in-between T0 and T3 (M =
82.5).
Discussion
Individuals who have a genetic predisposition to cancer
and their partners may experience difficulties during re-
productive decision-making (Derks-Smeets et al. 2014;
Gietel-Habets et al. 2018; Dekeuwer and Bateman 2013;
Ormondroyd et al. 2012; Dommering et al. 2010;
Donnelly et al. 2013; Van Asperen et al. 2002).
Incorporating an online decision aid in reproductive
counseling can be helpful for this target group (Derks-
Smeets et al. 2014; (de Die-Smulders et al. 2013). In
this study, the effects of an online decision aid were
assessed 3 months after its use.
Although we lack a concurrent control group, overall re-
sults of this study suggest that the decision aid contributes to
higher levels of informed decision-making in the oncogenetic
counseling setting. T0–T3 comparisons indicated a large and
significant overall effect for the outcome measures informed
decision-making, decisional conflict, knowledge, realistic ex-
pectations, level of deliberation, and decision self-efficacy.
Fig. 1 Informed decision-making
T0
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These results are in line with previous research indicating
reduced decisional conflict, increased knowledge regarding
potential options, and facilitation of informed decision-
making as possible positive effects of decision aids
(O’Connor and Jacobsen 2003; Juraskova et al. 2014;
Stacey et al. 2017).
Subgroup analyses indicated no significant effect on deci-
sion self-efficacy for participants who wish to have children in
the more distant future (> 2 years) and for participants who
had not had a consultation with a healthcare provider at base-
line or in-between T0 and T3. The increase in knowledge may
have contributed to the realization of the complexity of repro-
ductive decision-making. Another possible explanation might
be related to the fact that the decision aid is not capable of
providing psychological counseling or addressing emotional
issues as thoroughly as in an individualized counseling ses-
sion. Considering the complexity of the decision, for some
couples psychological counseling and addressing emotional
issues might be a prerequisite to further increase their confi-
dence in making a reproductive decision. For those couples a
consultation regarding the reproductive options with a coun-
selor before or after reviewing the decision aid might be need-
ed to further increase their self-efficacy.
Furthermore, although the decision aid resulted in a higher
likelihood of informed decision-making, still 42.0% of all
participants and 65.5% of the couples did not meet all three
Fig. 2 Informed decision-making
T3
J Community Genet
conditions for informed decision-making at T3. It is notable
that especially participants who wish to have children in the
more distant future (> 2 years) did not meet the conditions of
sufficient knowledge at T3; about half of these participants
still had insufficient knowledge, while the majority of the
participants who wish to have children in the near future (≤
2 years) reported sufficient knowledge. This finding was not
reflected in an overall lower engagement among participants
with a wish to have children in the more distant future
(Reumkens et al. 2018). We therefore tentatively assume that
this group is not as engaged yet in reproductive decision-
making and therefore may be less committed to making an
actual decision compared with those for whom reproductive
decision-making is a more pressing issue.
Further, the number of participants meeting all three con-
ditions for informed decision-making at T3 is relatively low
compared with other studies (Van den Berg et al. 2006; Lewis
et al. 2017; Lo et al. 2017). A possible explanation may lie in
the fact that in almost all studies participants received counsel-
ing whereas this is not the case for a considerable number of
participants in our study. The focus of this paper was also on
informed decision-making at the couple level. By definition a
couple is less likely to make an informed decision for both
partners compared with individuals making personal health
decisions. As the decision regarding reproductive options is
by nature a dyadic process, pertaining to the interaction be-
tween two persons, couples may benefit from the inclusion of
methods in the decision aid that further stimulate joint
decision-making among partners and facilitate the intra-
couple communication during reproductive decision-making.
This may contribute to higher levels of joint informed
decision-making among our target group. The inclusion of
measures of dyadic or joint decision-making would have pro-
vided more in-depth information on the interaction and com-
munication processes during reproductive decision-making
and the effect of the decision aid on these processes. To our
knowledge, currently no validated measurement tools exist to
assess such joint decision-making processes. We therefore
recommend future research to focus on exploring joint in-
formed decision-making and factors that influence related
processes.
An important limitation of this study relates to the use
of a pretest-posttest design restricting the internal validity
of this study. Maturation and history effects could not be
controlled for, and possible interference of other factors,
such as use of other information sources, cannot be ex-
cluded. However, the effects are probably mainly due to
the use of the decision aid as the effects were measured
immediately after use of the DA. This minimizes the risk
of possible bias of other factors such as counseling or
retrieval of additional information sources. Despite of
the fact that sample sizes are overall relatively small in
reproductive genetics, future studies should strive to use
an experimental design such as a randomized control trial
(RCT) which is capable of providing the strongest level of
evidence. Furthermore, this study included mainly partic-
ipants who were well-educated. Although this is in line
with general characteristics of oncogenetic counselees
(van der Giessen et al. 2017), future research should strive
to recruit patients with lower educational levels and lower
levels of health literacy and determine effects of decision-
al support among these subgroups. It was also not feasible
Table 3 Effects of decision aid
on outcome measures M (SD) T0 M (SD) T3 T p
Decisional conflict
Total score (0–100)* 28.16 (10.26) 14.16 (11.10) 6.83 < 0.001
Total score (excl. effective decision; 0–100) 36.97 (18.72) 29.21 (26.19) 2.21 0.029
Uncertainty subscale 49.68 (26.57) 28.46 (23.07) 8.06 < 0.001
Informed subscale 34.42 (19.98) 16.02 (15.40) 7.50 < 0.001
Values clarity subscale 37.34 (23.40) 16.99 (15.02) 7.66 < 0.001
Support subscale 33.66 (17.49) 18.51 (16.37) 7.16 < 0.001
Effective decision subscale* 23.70 (17.49) 11.20 (12.56) 4.19 < 0.001
Knowledge
Total score (0–15) 9.45 (2.80) 12.33 (1.78) − 9.40 < 0.001
Natural conception (0–3) 2.30 (0.67) 2.68 (0.55) − 5.81 < 0.001
PND (0–5) 2.17 (1.32) 3.88 (1.63) − 8.49 < 0.001
PGT (0–7) 4.97 (1.49) 6.59 (1.13) − 8.95 < 0.001
Realistic expectations (0–3) 0.75 (0.70) 1.17 (0.92) − 4.22 < 0.001
Level of deliberation (6–30) 23.36 (4.51) 25.54 (3.61) − 4.14 < 0.001
Decision self-efficacy (0–100) 76.45 (11.90) 84.50 (12.44) − 4.80 < 0.001
*N = 48 for T0–T3
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to collect information about non-participants. Therefore,
we were unable to calculate a response rate, nor report
on their reasons for non-participation. Additionally, the
dropout rate was 29% and the reasons for dropout are
unknown. Ideally, one should have information into the
reasons for non-responders and dropout as this might give
indications for improvement of the decision aid and the
willingness of the target population to use the decision
aid. However, in practice it is difficult to get this
information.
In conclusion, our findings suggest that the online decision
aid is an appropriate tool to effectively supplement standard
reproductive counseling to support persons having a genetic
predisposition to cancer and their partners in making an in-
formed reproductive decision. In order to make wider use of
the tool possible, the decision aid can be adapted to fit the
needs of couples with other hereditary conditions.
Several positive outcomes indicative of informed decision-
making were found 3 months after use of the decision aid.
Therewith use of the decision aid may lessen the negative
psychological impact of decision-making on couples’ daily
life and wellbeing. The decision aid is an appropriate tool to
be used in addition to reproductive counseling to support cou-
ples who are in need of reproductive decision support.
Currently we are conducting an explorative implementation
study to clarify optimal timing of providing the decision aid
and how to best incorporate the decision aid in daily practice.
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